We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genstruct and Gene Logic Collaborate on Systems Toxicology
News

Genstruct and Gene Logic Collaborate on Systems Toxicology

Genstruct and Gene Logic Collaborate on Systems Toxicology
News

Genstruct and Gene Logic Collaborate on Systems Toxicology

Read time:
 
Genstruct Inc. has announced that it has signed a partnership agreement with Gene Logic, an Ocimum Biosolutions company, for a systems toxicology collaboration.

As part of this collaboration, Gene Logic will provide its extensive toxicology databases and data on specific compounds obtained by the company's gene expression technology for preclinical and clinical research to clients from the pharmaceutical, biotechnology, consumer products and related industries. With its methodology and expertise in toxicity mechanisms, Genstruct will apply its Causal Network Modeling™ platform for systems biology to create network models that fully capture the toxicity potential of any compound.

"We are excited by the potential of combining the skill sets of the two companies," said Dr. Keith O. Elliston, president and CEO at Genstruct. "In Genstruct's work with pharmaceutical clients, we have characterized complex and poorly understood mechanisms of toxicity such as idiosyncratic drug-induced liver injury and hemangiosarcoma. We can now evaluate a new compound's potential to elicit these types of reactions in man based on data from simple animal studies. Partnering with a highly regarded data provider like Gene Logic, we can now offer pharmaceutical clients of both companies tremendous additional value in toxicity evaluation."

As part of this partnership, Genstruct and Gene Logic will participate in co-marketing initiatives to extend each other's offerings to current and potential clients. In addition, the companies intend to collaborate in other areas, including personalized or individualized oncology therapy. "Here, Genstruct will engage with Gene Logic to generate gene expression data from patient tumors which will be analyzed using our systems biology platform to arrive at a comprehensive network-level understanding of an individual patient's disease. This could be of great value to physicians in devising optimal therapy for each patient," added Dr. Elliston.
Advertisement